99 related articles for article (PubMed ID: 30318081)
1. HeberFERON, a new formulation of IFNs with improved pharmacodynamics: Perspective for cancer treatment.
Bello-Rivero I; Garcia-Vega Y; Duncan-Roberts Y; Vazquez-Blomquistc D; Santana-Milian H; Besada-Perez V; Rios-Cabrera M
Semin Oncol; 2018 Jan; 45(1-2):27-33. PubMed ID: 30318081
[TBL] [Abstract][Full Text] [Related]
2. A co-formulation of interferons alpha2b and gamma distinctively targets cell cycle in the glioblastoma-derived cell line U-87MG.
Miranda J; Vázquez-Blomquist D; Bringas R; Fernandez-de-Cossio J; Palenzuela D; Novoa LI; Bello-Rivero I
BMC Cancer; 2023 Aug; 23(1):806. PubMed ID: 37644431
[TBL] [Abstract][Full Text] [Related]
3. Proteomics and Phospho-Proteomics Profiling of the Co-Formulation of Type I and II Interferons, HeberFERON, in the Glioblastoma-Derived Cell Line U-87 MG.
Vázquez-Blomquist D; Hardy-Sosa A; Baez SC; Besada V; Palomares S; Guirola O; Ramos Y; Wiśniewski JR; González LJ; Bello-Rivero I
Cells; 2022 Dec; 11(24):. PubMed ID: 36552831
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.
García-Vega Y; García-García I; Collazo-Caballero SE; Santely-Pravia EE; Cruz-Ramírez A; Tuero-Iglesias AD; Alfonso-Alvarado C; Cabrera-Placeres M; Castro-Basart N; Duncan-Roberts Y; Carballo-Treto TI; Soto-Matos J; Izquierdo-Toledo Y; Vázquez-Blomquist D; García-Iglesias E; Bello-Rivero I
BMC Pharmacol Toxicol; 2012 Dec; 13():20. PubMed ID: 23272809
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteers.
García-García I; Hernández-González I; Díaz-Machado A; González-Delgado CA; Pérez-Rodríguez S; García-Vega Y; Campos-Mojena R; Tuero-Iglesias ÁD; Valenzuela-Silva CM; Cruz-Ramírez A; Martín-Trujillo A; Santana-Milián H; López-Saura PA; Bello-Rivero I;
BMC Pharmacol Toxicol; 2016 Dec; 17(1):58. PubMed ID: 27923408
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
[TBL] [Abstract][Full Text] [Related]
7. Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890).
Dutcher JP; Fine JP; Krigel RL; Murphy BA; Schaefer PL; Ernstoff MS; Loehrer PJ
Med Oncol; 2003; 20(3):271-81. PubMed ID: 14514977
[TBL] [Abstract][Full Text] [Related]
8. A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma.
Ernstoff MS; Nair S; Bahnson RR; Miketic LM; Banner B; Gooding W; Day R; Whiteside T; Hakala T; Kirkwood JM
J Clin Oncol; 1990 Oct; 8(10):1637-49. PubMed ID: 2120392
[TBL] [Abstract][Full Text] [Related]
9. Regression of skin recurrences of breast carcinomas treated with intralesional injections of natural interferons alpha and gamma.
Habif DV; Ozzello L; De Rosa CM; Cantell K; Lattes R
Cancer Invest; 1995; 13(2):165-72. PubMed ID: 7874570
[TBL] [Abstract][Full Text] [Related]
10. Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial.
Shin DM; Khuri FR; Murphy B; Garden AS; Clayman G; Francisco M; Liu D; Glisson BS; Ginsberg L; Papadimitrakopoulou V; Myers J; Morrison W; Gillenwater A; Ang KK; Lippman SM; Goepfert H; Hong WK
J Clin Oncol; 2001 Jun; 19(12):3010-7. PubMed ID: 11408495
[TBL] [Abstract][Full Text] [Related]
11. Interferon alpha-2b and retinoic acid combined treatment affects proliferation and gene expression of human cervical carcinoma cells.
Lancillotti F; Giandomenico V; Affabris E; Fiorucci G; Romeo G; Rossi GB
Cancer Res; 1995 Jul; 55(14):3158-64. PubMed ID: 7606736
[TBL] [Abstract][Full Text] [Related]
12. Prevention of lethal respiratory vaccinia infections in mice with interferon-alpha and interferon-gamma.
Liu G; Zhai Q; Schaffner DJ; Wu A; Yohannes A; Robinson TM; Maland M; Wells J; Voss TG; Bailey C; Alibek K
FEMS Immunol Med Microbiol; 2004 Apr; 40(3):201-6. PubMed ID: 15039095
[TBL] [Abstract][Full Text] [Related]
13. Orally administered IFN-alpha acts alone and in synergistic combination with intraperitoneally administered IFN-gamma to exert an antitumor effect against B16 melanoma in mice.
Fleischmann WR; Masoor J; Wu TY; Fleischmann CM
J Interferon Cytokine Res; 1998 Jan; 18(1):17-20. PubMed ID: 9475662
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12.
Eisenbeis CF; Lesinski GB; Anghelina M; Parihar R; Valentino D; Liu J; Nadella P; Sundaram P; Young DC; Sznol M; Walker MJ; Carson WE
J Clin Oncol; 2005 Dec; 23(34):8835-44. PubMed ID: 16314644
[TBL] [Abstract][Full Text] [Related]
15. Sequential treatment of Ph-positive chronic myeloid leukemia with interferon gamma and interferon alpha.
Russo D; Fanin R; Zuffa E; Damiani D; Gallizia C; Michieli M; Testoni N; Benfenati D; Visani G; Zaccaria A
Haematologica; 1990; 75(4):334-9. PubMed ID: 2125966
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951).
Aass N; De Mulder PH; Mickisch GH; Mulders P; van Oosterom AT; van Poppel H; Fossa SD; de Prijck L; Sylvester RJ
J Clin Oncol; 2005 Jun; 23(18):4172-8. PubMed ID: 15961764
[TBL] [Abstract][Full Text] [Related]
17. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.
Motzer RJ; Murphy BA; Bacik J; Schwartz LH; Nanus DM; Mariani T; Loehrer P; Wilding G; Fairclough DL; Cella D; Mazumdar M
J Clin Oncol; 2000 Aug; 18(16):2972-80. PubMed ID: 10944130
[TBL] [Abstract][Full Text] [Related]
18. Granulocyte-macrophage colony-stimulating factor and interferon-alpha 2B in patients with advanced renal cell carcinoma.
Lümmen G; Sperling H; Luboldt H; Otto T; Rübben H
Urol Int; 1998; 61(4):215-9. PubMed ID: 10364752
[TBL] [Abstract][Full Text] [Related]
19. [Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. A retrospective study comparing interferon-alpha-2a/vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil].
May M; Helke C; Bock M; Hoschke B
Urologe A; 2004 Sep; 43(9):1111-9. PubMed ID: 15232686
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of combinations of recombinant interferons beta(ser) and gamma in patients with advanced malignancy.
Schiller JH; Storer B; Willson JK; Borden EC
Cancer Treat Rep; 1987 Oct; 71(10):945-52. PubMed ID: 3115570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
